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ABSTRACT
Background: Neoadjuvant chemotherapy followed by surgery is the standard 
of care for UK patients with locally advanced resectable oesophageal carcinoma 
(OeC). However, not all patients benefit from multimodal treatment and there 
is a clinical need for biomarkers which can identify chemotherapy responders. 
This study investigated whether the proportion of tumour cells per tumour area 
(PoT) measured in the pre-treatment biopsy predicts chemotherapy benefit for 
OeC patients.
Patients and methods: PoT was quantified using digitized haematoxylin/eosin 
stained pre-treatment biopsy slides from 281 OeC patients from the UK MRC OE02 trial 
(141 treated by surgery alone (S); 140 treated by 5-fluorouracil/cisplatin followed by 
surgery (CS)). The relationship between PoT and clinicopathological data including 
tumour regression grade (TRG), overall survival and treatment interaction was 
investigated.
Results: PoT was associated with chemotherapy benefit in a non-linear fashion 
(test for interaction, P=0.006). Only patients with a biopsy PoT between 40% and 
70% received a significant survival benefit from neoadjuvant chemotherapy (N=129; 
HR (95%CI):1.94 (1.39-2.71), unlike those with lower or higher PoT (PoT<40%, 
N=39, HR:1.25 (0.66-2.35); PoT>70% (N=28, HR:0.65 (0.36-1.18)). High 
pre-treatment PoT was related to lack of primary tumour regression (TRG 4 or 5), 
P=0.0402.
Conclusions: This is the first study to identify in a representative subgroup of 
OeC patients from a large randomized phase III trial that the proportion of tumour 
in the pre-chemotherapy biopsy predicts benefit from chemotherapy and may be a 
clinically useful biomarker for patient treatment stratification.
                  Research Paper
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KEY MESSAGE
Proportion of tumour is a novel biomarker which can be measured in the pre-
treatment diagnostic biopsy and which may enable the identification of chemotherapy 
responders and non-responders among patients with oesophageal carcinoma. 
Proportion of tumour could easily become part of the routine reporting of oesophageal 
cancer biopsies and may aid in managing patients with borderline resectable cancer.
INTRODUCTION
Oesophageal cancer (OeC) is the 6th commonest 
cause of cancer death worldwide, accounting for 
approximately 400,000 cancer-related deaths in 2012 [1]. 
At the time of diagnosis, OeC is potentially resectable, 
and thus potentially curable, in 30% of patients. The 
cornerstone of curative OeC treatment is surgical resection 
preceded by neoadjuvant combination chemotherapy 
(NAC) or chemoradiotherapy to downstage the disease, 
enable complete resection and eliminate micrometastases 
preventing recurrent metastatic disease [2–6].
Only a relatively small subset of patients with 
resectable OeC appear to have long-term benefit from 
multimodality treatment whereas chemotherapy non-
responders may have an unnecessarily prolonged wait 
for surgery with potential tumour progression and toxic 
side effects [6, 7]. In order to optimize treatment for 
OeC patients, there is an urgent clinical need to identify 
biomarkers that predict local tumour response and 
longterm chemotherapy benefit, ideally using the routine 
diagnostic endoscopic biopsy material.
Like most other malignant tumours, OeC are 
composed of tumour cells and intratumoural stroma 
(extracellular matrix, fibroblasts, vessels, immune cells etc.). 
Intratumoural stroma varies in quantity and quality and has 
been shown to influence malignant transformation, tumour 
invasion and metastasis (for review see Hanahan et al. [8]). 
Stroma abundance has been related to poor patient prognosis 
[9–22]. Intratumoural stroma has also been associated with 
chemotherapy resistance by fibroblast proteins inhibiting 
tumour cell apoptosis [23] or by reducing chemotherapy 
delivery [24]. To date, there have been no studies published 
investigating the role of the proportion of tumour (PoT), i.e. 
the relative amount of tumour cells and intratumoural stroma 
in the tumour area, in predicting local tumour response and 
survival benefit from cytotoxic combination chemotherapy.
This study tested the hypothesis that high PoT 
(e.g. low intratumoural stroma content) in the pre-
treatment biopsy predicts benefit from neoadjuvant 
chemotherapy in OeC patients. PoT was quantified in 
the routine diagnostic pre-treatment endoscopic biopsy 
slides from OeC patients randomized to treatment with 
either surgery alone (S group) or chemotherapy followed 
by surgery (CS group) within the UK MRC OE02 trial 
(ISRCTN 43987580) [2]. The relationship between PoT 
and clinicopathological data including pathological 
tumour regression grade, overall survival and treatment 
interaction effect was investigated.
RESULTS
Patients and clinicopathological data
Biopsy material from 281 OE02 trial patients (140 
patients from the chemotherapy followed by surgery 
(CS) group and 141 patients from the surgery alone 
(S) group) was included in the current study (details of 
material retrieval and case drop outs are shown Figure 1). 
Patient median age was 62 years (range: 30 to 83 years). 
Two hundred and thirteen patients (76%) were male, 195 
patients (69%) had adenocarcinoma, 84 patients (30%) 
had squamous cell carcinoma and 2 patients (1%) had 
undifferentiated carcinomas. Baseline characteristics of 
the patients included in the study were similar between 
the two treatment arms and similar to the whole OE02 
trial cohort with respect to survival (HR=0.97 95%CI: 
0.83-1.14, P=0.72) and clinicopathological data 
(Supplementary Table S1).
Inter-observer variation of proportion of tumour 
measurement
Double scoring of 10% of tissue pieces (48 475 
measurement points) demonstrated 95.54% agreement for 
individual measurement points between the two observers 
(κ=0.937, 95% confidence interval (CI): 0.935 to 0.938, 
P<0.0001).
After calculating the PoT per piece for each 
observer and using the methodology described by Bland-
Altman, [25] the mean difference in PoT between the two 
observers was 2% (95%CI:1.3 to 2.8%).
Relationship between proportion of tumour and 
clinicopathological data
In total, 838 tissue pieces from 281 patients were 
measured and a total of 498,497 measurement points 
were categorized. The median number of tissue pieces per 
patient was 5 (range: 1 to 20 pieces). The median number 
of tissue pieces meeting the inclusion criteria for analysis 
(see methods) was 3 (range: 1 to 12 pieces). The median 
size of the region of interest per patient was 1.44 mm2 
(range: 0.04 mm2 to 23.2 mm2).
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The median proportion of tumour (PoT) per 
patient was 56% (range: 15% to 100%), 85% of patients 
had a PoT between 25% and 75%. PoT in the pre-
treatment biopsy was not different between the CS 
group and the S group (CS median PoT: 56% (range: 
17 to 89%); S median PoT: 55% (range: 15 to 99%), 
P=0.467). PoT of squamous cell carcinoma biopsies 
was significantly higher than that of adenocarcinoma 
biopsies (squamous cell carcinoma median PoT: 
58% (range: 17 to 93%); adenocarcinoma median 
PoT: 55% (range: 15 to 99.5%), P=0.0357). When 
analyzing the data of the whole patient cohort, there 
was no relationship between PoT and age (P=0.3096), 
gender (P=0.6571), tumour location (P=0.6391), grade 
of differentiation (P=0.7409), degree of dysphagia 
(P=0.0626) or World Health Organization performance 
status (P=0.6382). Representative images of the PoT 
groups (PoT <40%, 40-70% and >70%) are shown in 
Supplementary Figure S1. The associations between the 
PoT categories and the clinicopathological variables are 
shown in Supplementary Table S2.
Investigating the patients with biopsy and matched 
resection specimens (N=111), there was no significant 
relationship between biopsy PoT (classified as PoTlow, 
PoTmedium, PoThigh, see below) and depth of invasion 
(T category) or lymph node status (N category) neither 
Figure 1: Consort diagram showing the details of biopsy material retrieval from the OE02 trial patients
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for CS patients (P=0.2722 and P=0.5021, respectively) 
nor for S patients (P=0.1570 and P=0.8851, respectively).
Relationship between proportion of tumour in 
the pre-treatment biopsy and Mandard tumour 
regression grade in the resected specimen
Matched resection specimens to determine Mandard 
tumour regression grade (TRG) were available for 111 
(79%) of the 140 CS patients with PoT data. Evidence of 
tumour regression, defined as Mandard TRG 1, 2 or 3, was 
seen in 18 (16%) OeC. When analysed as a continuous 
variable, PoT in the pre-treatment biopsy was significantly 
higher in cases with no evidence of tumour regression 
(TRG 4 or 5) (median PoT: 57% (range: 17 to 86%)) 
compared to those with evidence of tumour regression 
(TRG 1, 2 or 3) (median PoT: 52%, (range: 25 to 75%)), 
P=0.0402, Supplementary Figure S2.
Relationship between proportion of tumour in 
the pre-treatment biopsy and patient survival
The prognostic value of PoT is summarized in Table 
1. Among patients treated with surgery only, there was a 
trend that patients with a higher PoT had a longer survival 
(log-rank trend P-value 0.0359). For CS patients, a non-
linear association between PoT and patient survival was 
seen. CS patients with PoTmed (≥ 40% ≤ 70%) tumours 
had a significantly longer overall survival than those 
with PoTlow (<40%) or PoThigh (>70%) tumours with 
evidence of a treatment interaction effect (P-value of test 
for heterogeneity = 0.006), see Table 1. When comparing 
treatment arms, only patients with PoTmed in the pre-
treatment biopsy demonstrated a significant survival 
benefit from chemotherapy (HR 1.94 (95%CI: 1.39-2.71, 
P-value<0.001), Figure 2 and Table 2. No difference in 
overall survival was seen between CS patients and S 
patients with PoTlow tumours (HR 1.25, 95%CI: 0.66-
2.35, P=0.490) or PoThigh tumours (HR 0.65, 95%CI: 
0.36-1.18, P=0.157), suggesting that OE02 trial patients 
with a PoThigh tumour in the diagnostic biopsy may 
benefitted most from treatment with surgery alone.
The relationship between PoTlow, PoTmed and 
PoThigh and survival was similar when the analyses were 
restricted to the subgroup of patients with adenocarcinoma 
(CS: N=98, S: N=97). Among adenocarcinoma patients 
with PoTmedium biopsies, a longer survival was seen for 
CS patients with evidence of a treatment interaction effect 
(P-value of test for heterogeneity = 0.046), Supplementary 
Table S3. As with the full cohort, only patients with 
PoTmed biopsies demonstrated a significant survival 
benefit from treatment with neoadjuvant chemotherapy 
(Figure 3). No significant difference in survival and 
no treatment interaction effect was observed among 
adenocarcinoma patients with PoThigh or PoTlow 
tumours (Figure 3).
Table 1: Prognostic value of proportion of tumour by treatment arm
Pre-op chemotherapy followed by surgery Surgery alone
PoT grouping N Median 
OS
HR (95% CI) N Median 
OS
HR (95% CI)
Continuous 140 1.00 (0.99, 1.01) 141 0.99 (0.98, 1.00)
Binary
<50% 51 1.25 1 49 1.45 1
≥50% 89 1.85 0.83 (0.56, 1.23) 92 1.10 0.93 (0.65, 1.34)
Tertiles
≤49.15 47 1.11 1 47 1.45 1
49.16 – 64.03 49 1.92 0.71 (0.45, 1.13) 46 1.05 1.10 (0.72, 1.68)
>64.03 44 1.46 0.92 (0.59, 1.46) 48 1.11 0.84 (0.54, 1.30)
Final grouping
<40 29 0.95 1* 17 1.21 1†
40-70 84 1.98 0.59 (0.37, 0.97)* 99 1.10 0.75 (0.44, 1.27)†
≥70 27 1.20 1.20 (0.69, 2.11)* 25 1.78 0.50 (0.26, 0.97)†
Values of significance are highlighted and typed in bold. Abbreviations: CI: confidence interval: HR: hazard ratio; OS: 
overall survival (years); PoT: proportion of tumour.
*test for interaction of heterogeneity of treatment effect across groups, P=0.006
† log-rank trend P-value=0.0359
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Figure 2: Relationship between treatment and overall survival by proportion of tumour class (whole cohort). 
A. Proportion of tumour < 40%. There is no significant difference in overall survival between patients treated with chemotherapy followed 
by surgery (n=29) compared to those treated by surgery alone (n=17). B. Proportion of tumour between 40% and 70%. Patients treated with 
chemotherapy followed by surgery (n=84) survived significantly longer than patients treated with surgery only (n=99). C. Proportion of 
tumour > 70%. There is no significant difference in overall survival between patients treated with chemotherapy followed by surgery (n=27) 
compared to those treated by surgery alone (n=25).
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DISCUSSION
This is the first study to investigate whether 
the proportion of tumour (PoT) in the pre-treatment 
endoscopic biopsies can predict local tumour response 
and benefit from neoadjuvant combination chemotherapy 
in patients with oesophageal cancer (OeC) from the 
randomized UK MRC OE02 phase III trial. Using virtual 
slides and quantitative morphometry with near perfect 
inter-observer agreement, we demonstrated that the 
biopsy PoT is able to identify patients who benefitted from 
chemotherapy. However, to our surprise, the relationship 
between PoT and survival was not linear. Only patients 
with a PoT between 40% and 70% derived a significant 
benefit from neoadjuvant chemotherapy. Furthermore, 
comparison between the two treatment arms suggests 
that for patients with a very high PoT, survival following 
treatment with neoadjuvant chemotherapy may be poorer 
compared to treatment by surgery alone. To date, no 
studies have performed a similar investigation on clinical 
material in either oesophageal cancer or in any other 
cancer types treated with neoadjuvant chemotherapy. 
None of the previous studies, which investigated PoT as 
a prognostic marker, identified a non-linear relationship 
between PoT and survival. This could be related to the fact 
that previous studies didn't use quantitative morphometry 
methods which generate continuous data that can be 
explored in detail or that investigators dichotomized 
their datasets right from the start of the analysis [10, 11, 
20, 21]. We can show that this potentially biologically 
and clinically important phenomenon would also have 
been missed in our study had we used binary cut offs for 
analyses (Table 1).
Recent preclinical studies suggest that improved 
chemotherapy response in cancers with high intratumoural 
stroma content may be related to both, the structural 
components and protein products of the intratumoural 
stroma [23]. The presence of intratumoural stroma has 
been shown to modify the three-dimensional structure 
and composition of the tumour [26], which may result 
in an increase in interstitial fluid pressure, collapse of 
the microvasculature and reduction in tumour perfusion 
and chemotherapy drug delivery [24]. Furthermore, it 
has been suggested that tumour stroma produced proteins 
involved in vessel maturation and integrity such as VEGF, 
TFF-β, Ang1/2 and matrix metalloproteinases might 
result in the formation of a structurally and functionally 
abnormal tumour vasculature with areas of shunting and 
blind loops [27]. Hypoperfused tumour areas may a) 
not be reachable by chemotherapeutic drugs and b) may 
become hypoxic. Hypoxia has been suggested as one 
possible mechanism of cancer cell resistance to cytotoxic 
chemotherapy [28]. In addition, cancer associated 
fibroblasts have been shown to secrete fibronectin, 
connective tissue growth factor, hyaluron, matrix 
metalloproteinase and syndecan 1. These proteins have 
been suggested to induce cancer cell chemoresistance by 
reducing cell sensitivity to apoptosis and upregulating the 
expression of the multidrug resistance protein ABCB1 
[23]. Contrastingly, however, tumour cells grown in cell 
culture in direct contact with each other (simulating the 
absence of stroma) have been shown to be more resistant 
to alkylating and platinum agents than the same cells after 
disaggregation [29, 30].
Based on our findings, we can currently only 
speculate that a fine balance between stroma abundance 
and tumour cell abundance might be necessary for 
chemotherapy to be most effective. Thus, patients may 
derive little or no benefit from chemotherapy if their 
cancers have a very high proportion of stroma (PoTlow) 
or very high proportion of tumour cells (PoThigh).
The ability of PoT to predict local tumour response 
(e.g. primary tumour regression) may be clinically useful 
for the pre-treatment assessment of borderline resectable 
cancers. However, we were unable to directly assess 
whether the response of the primary tumour was related 
to clinical downstaging of the tumour as detailed clinical 
and radiological staging data at the time of diagnosis were 
not collected in the OE02 trial [2]. Given the complexity 
and abundance of interactions between the intratumoural 
stroma and tumour cells in the presence of chemotherapy 
[23], further characterization of the tumour stroma 
components and their interaction with tumour cells is 
required to fully understand the biological mechanisms 
underpinning the findings of this study. Such studies may 
not only reveal basic principles of tumour cell and stroma 
Table 2: Predictive value of proportion of tumour
Pre-op chemotherapy followed 
by surgery
Surgery alone HR (95% CI)
PoT grouping N Median OS N Median OS
PoTlow (<40%) 29 0.95 17 1.21 1.25 (0.66 - 2.35)
PoTmed (40-70%) 84 1.98 99 1.10 1.94 (1.39 - 2.71)*
PoThigh (>70%) 27 1.20 25 1.78 0.65 (0.38 – 1.18)
Values of significance are highlighted and typed in bold. Abbreviations: CI: confidence interval: HR: hazard ratio; OS: 
overall survival (years); PoT: proportion of tumour.
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Figure 3: Relationship between treatment and overall survival by proportion of tumour class (adenocarcinoma patients 
only). Relationship between treatment and overall survival by proportion of tumour class (adenocarcinoma patients only) A. Proportion of 
tumour < 40%. There is no significant difference in overall survival between adenocarcinoma patients treated with chemotherapy followed 
by surgery (n=24) compared to those treated by surgery alone (n=14) B. Proportion of tumour between 40% and 70%. Adenocarcinoma 
patients treated with chemotherapy followed by surgery (n=61) survived significantly longer than patients treated with surgery only (n=68). 
C. Proportion of tumour > 70%. There is no significant difference in overall survival between adenocarcinoma patients treated with 
chemotherapy followed by surgery (n=13) compared to those treated by surgery alone (n=15).
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interaction but may also identify new therapeutic targets 
in patients with both oesophageal and other epithelial 
cancers.
Limitations of our study include that we were 
only able to retrieve pre-treatment biopsy material from 
a subset of OE02 trial patients which was also related 
to the fact that at the time of the OE02 trial 129 (16%) 
patients were diagnosed by cytology only, or material 
was no longer present in the archive. Not all patients had 
matched resection specimens available, due to either the 
patient not undergoing surgery or material could not be 
retrieved. However, no difference was seen between the 
clinical and survival data of the patients who did and did 
not have biopsies available for analysis confirming that 
the investigated subgroup of patients was representative 
of the whole trial cohort. The amount of material 
available for assessment varied between different 
patients, a factor we compensated for by measuring 
biopsy pieces individually and adjusting the results by 
the size of the measurement area.
We are unable to directly validate the results from 
this study in a second independent phase 3 randomized 
trial cohort, as the OE02 trial changed clinical practice 
and there is no other trial in this patient population with 
a surgery alone control arm allowing to distinguish 
prognostic and predictive value of the biomarker.
In conclusion, this exploratory study is the first to 
demonstrate that proportion of tumour measurement in the 
diagnostic biopsies of patients with oesophageal cancer 
may be a clinically useful biomarker to stratify patients for 
treatment. Future studies into the tumour stroma content 
should use continuous measurement scales to allow 
non-linear associations to be detected. Further research 
is needed to refine the prediction model by detailed 
quantitative morphological and molecular characterization 
of the intratumoural stroma including its components to 
better understand the underlying biological processes and 
ultimately improve patient treatment stratification.
MATERIALS AND METHODS
Ethics statement
This study has been conducted in accordance with 
the ethical standards and according to the Declaration 
of Helsinki and according to national and international 
guidelines and was approved by the South East Research 
Ethics Committee, London, UK REC reference: 07/
H1102/111.
Patients
Eight hundred and two patients with microscopically 
or cytologically confirmed, previously untreated, 
resectable cancer of the oesophagus were included in 
the UK Medical Research Council (MRC) OE02 trial. 
Patients were randomized to treatment by surgery alone 
(S patients) or neoadjuvant combination chemotherapy 
consisting of two cycles 5-fluorouracil and cisplatin 
followed by surgery (CS patients) [2].
The Haematoxylin/Eosin (H&E) slide and/or 
blocks of the formalin fixed paraffin embedded diagnostic 
biopsies were retrospectively collected from 366 patients. 
Only tissue samples with a minimum of 0.04 mm2 tumour 
containing area were included in order to allow fitting of a 
minimum of 400 PoT measurement points. Samples with 
collections of malignant cells without intervening stroma, 
or no invasive malignancy were excluded. Material from 
281 patients (140 CS patients and 141 S patients) fulfilled 
the inclusion criteria for the current study. Material 
retrieval and selection are shown in Figure 1.
Clinicopathological data
Clinical data including age at randomization, cancer 
location (upper, middle or lower third of oesophagus), 
degree of dysphagia and patient performance status were 
collected during the clinical trial [2]. H&E slides from the 
biopsy and resection specimens were centrally reviewed 
at the time of slide and block collection to determine the 
histological tumour type, poorest grade of differentiation, 
tumour regression grading according to Mandard et al, 
[31] depth of invasion and lymph node status according 
to the Union for International Cancer Control TNM 
classification 6th ed [32]. Histopathological data that were 
not assessable on review of the slide, such as tumour size, 
tumour location or number of lymph nodes were extracted 
from the original pathology report.
Morphometric analysis of the biopsy and 
calculation of the proportion of tumour
The tumour and intratumoural stroma content was 
quantified using point counting with random systematic 
tissue sampling, a technique well-established for 
morphometric object quantification [33–36]. The original 
H&E stained diagnostic biopsy slides were used whenever 
possible. If the original slide was not available, 4 μm 
thick sections were cut from the biopsy paraffin block 
and stained with H&E using a standard protocol. For 35 
patients, tumour cells were extremely difficult to identify 
on the H&E section and an additional slide was subjected 
to immunohistochemical staining with an epithelial 
cell marker (pan-cytokeratin, clone#:AE1/AE3 (Dako 
Cytomation), 1:100) using a routine protocol. Cytokeratin 
stained slides were quantified using the same protocol as 
for H&E stained slides.
All slides were scanned at 40x magnification using 
an Aperio XT scanner (Aperio Technologies, Vista, CA, 
USA) and examined using digital slide viewer software 
(ImageScopev11.1.2.752, Aperio Technologies, Vista, CA, 
USA). Regions with invasive tumour were identified and 
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outlined using a tablet and pen tool (Cintiq 21UX LCD 
tablet, DTZ-2100D, Wacom). The software calculated 
automatically the size of the individually outlined region 
of interest. Areas consisting of necrosis, normal tissue or 
dysplasia were excluded. For the 837 regions identified, a 
random systematic grid of 600 measurement points +5% 
tolerance was generated within the outline using virtual 
graticule software (RandomSpot, University of Leeds, 
Leeds, UK), [36]. Only one region was too small to fit 
600 points and was therefore fitted with 400 measurement 
points. Each measurement point was manually reviewed 
and the tissue category underlying the measurement 
point was classified as tumour (T), intratumoural stroma 
(St: stroma, vessel, inflammation, or muscle) or non-
informative (necrosis, extracellular mucin, normal tissue, 
keratin or non-classifiable due to artefacts). The method 
of outlining, superimposed grid and point counting is 
illustrated in Supplementary Figure S3.
Proportion of tumour cells (PoT) per case was 
calculated as the mean PoT of all biopsy pieces. To 
account for different sizes of the tissue regions, the 
PoT value per patient was normalized by the size of 
the measurement region so that the PoT per region was 
established as: ((number of points classified as T/number 
of points classified as either T or St)X(area of biopsy 
piece/total area of biopsy tissue per patient))x100.
Interobserver variation of the morphometric 
measurement was investigated by doublescoring a 
randomly selected sample of 10% of tissue pieces by 
a second independent histopathologist. Interobserver 
variation was assessed using Cohen's Kappa co-efficient 
(κ). The limits of agreement between observers were 
calculated using Bland-Altman plots. [25]
Statistical methods
To assess whether the patient subset included 
in the study is representative of the whole OE02 trial 
population, patient characteristics (gender, site of tumour, 
histology, age, resection status (whether a resection was 
macro/microscopically complete) and tumour size) were 
compared between patients with and without PoT data.
The primary outcome measure for assessing the 
prognostic and predictive value of PoT was overall 
survival (time from randomization until death or 
last follow-up). Disease free survival was not used 
as an endpoint due to the absence of accurate data on 
oncological completeness of patient resections and 
uncertainty regarding the assessment methods used 
to diagnose disease recurrence. Data are presented 
graphically using Kaplan-Meier plots, and comparisons 
were made using log-rank tests and hazard ratios. 
Treatment interaction was assessed by calculating the 
heterogeneity of treatment effect across groups using 
a partial likelihood ratio test. Cox regression models 
included treatment, PoT, and interaction terms.
Tumour regression of the primary tumour in the 
resection specimen after chemotherapy was graded 
according to Mandard et al. [31] and compared with the 
pre-treatment biopsy PoT.
Categorical data were summarized using counts 
and percentages and continuous data using medians, 
ranges and inter-quartile ranges. Comparisons were 
made using chi-square, Kruskal-Wallis, Wilcoxon test or 
correlation coefficients as appropriate. As the analyses 
were hypothesis generating, no adjustments were made 
to account for multiple testing. Analyses were conducted 
using Stata Statistical Software: Release 12, College 
Station, TX: StataCorp LP or SPSS v.19, IBM Company, 
New York, New York State, USA.
To assess the prognostic and predictive value of 
the pre-treatment biopsy PoT, the data were analyzed 
using (1) PoT as a continuous variable, (2) a previously 
reported 50% cut off [20, 21] and (3) exploratory analyses 
to identify the optimal cut off by grouping patients by 
PoT values into three equally sized groups (PoT cut offs 
for three equal sized groups ≤49.15, 49.15 to 63.03 and 
≥63.03). This initial analysis using tertiles suggested a 
greater benefit from chemotherapy in the middle tertile and 
no clear benefit to those in the upper and lower tertiles. To 
refine the cut off values, the data and relationship with 
survival were further explored by grouping patients into 
five equally sized groups (PoT cut offs for five equally 
sized groups: ≤41.86%, 41.86 to 51.39, 51.39 to 59.73, 
59.73 to 69.38 and >69.38). Kaplan-Meier plots per 
treatment arm for the five equally sized groups are shown 
in Supplementary Figure S4. After visual assessment of 
the quintile Kaplan-Meier plots and with the aim to find 
a cut off that can relatively easily be assessed in future 
studies, patients were grouped as PoTlow (< 40%, N=46), 
PoTmedium (≥40% and ≤70%, N=183) and PoThigh 
(>70%, N=52).
The change in treatment effect across the full range 
of PoT values was further investigated using multivariable 
fractional polynomials, shown in Supplementary Figure 5.
The relationship between PoT and overall survival 
was examined within and between treatment arms.
A multivariate analysis including known prognostic 
factors such as depth of invasion and lymph node status as 
well as PoT class was found to be unfeasible as the PoT 
values were generated from the diagnostic (pre-treatment) 
biopsies and detailed pre-treatment staging data were not 
collected in this trial [2]. Using the pathological stage data 
after surgery was not an option as in patients treated with 
neoadjuvant chemotherapy, the stage could have been 
changed related to the chemotherapy.
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